Intellia, Holder of Rights to UC’s CRISPR Technology, to Win China Patent – Genetic Engineering & Biotechnology News
|
Intellia, Holder of Rights to UC’s CRISPR Technology, to Win China Patent
Genetic Engineering & Biotechnology News Intellia Therapeutics, said today it received notice from China’s State Intellectual Property Office (SIPO) that it will grant the company a broad patent covering CRISPR/Cas9 single-guide gene editing methods and compositions. CRISPR stands for … BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in ChinaReuters Intellia Therapeutics Announces Patent for CRISPR/Cas Genome …Nasdaq CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in ChinaEconoTimes BBNS all 11 news articles » |
|
J&J Immunotherapy Darzalex Ok’d for Expanded Combination Use
Nasdaq Johnson & JohnsonJNJ announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation’s CELG multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone. The combination has been approved … |
Penn State News |
Grape-based compounds kill colon cancer stem cells in mice
Penn State News UNIVERSITY PARK, Pa. — Compounds from grapes may kill colon cancer stem cells both in a petri dish and in mice, according to a team of researchers. The compounds — resveratrol —which are found in grape skins and seeds, could also eventually lead to … |
|
BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in ChinaNasdaq Intellia Therapeutics Announces Patent for CRISPR/Cas Genome …GuruFocus.com |
|
BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … Intellia Therapeutics Announces Patent for CRISPR/Cas Genome …GuruFocus.com Intellia Therapeutics Inc – Receive News & Ratings DailyBBNS |
|
J&J Immunotherapy Darzalex Ok’d for Expanded Combination Use
Zacks.com Johnson & Johnson (JNJ – Free Report) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation’s (CELG – Free Report) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone. |